Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)

SHA:600566 Revenue

Hubei Jumpcan Pharmaceutical had revenue of 1.31B CNY in the quarter ending September 30, 2026, with 10.62% growth. This brings the company's total for the last twelve months to 5.92B, down -3.58% year-over-year. In the year 2025, Hubei Jumpcan Pharmaceutical had annual revenue of 6.22B, down -22.43%. That makes Hubei Jumpcan Pharmaceutical the 8,170th largest company in the world by revenue and 1,245th in China.

• Revenue (ttm): 5.92B
• Revenue Growth: -3.58%
• P/S Ratio: 4.29
• Revenue / Employee: 1.43M
• Employees: 4,137
• Market Cap: 25.43B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Clearing Heat and Detoxifying 1.99B 32.0%
• Pediatrics 1.65B 26.7%
• Digestive 956.02M 15.4%
• Other 797.53M 12.9%
• Breathing 467.04M 7.5%
• Commercial 254.31M 4.1%
• Cardiovascular Type 60.79M 1.0%
• Gynecology 30.25M 0.5%

Fiscal year ended Dec 31, 2025 See the full SHA:600566 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.22B	-1.80B	-22.43%
Dec 31, 2024	8.02B	-1.64B	-16.96%
Dec 31, 2023	9.65B	658.17M	7.32%
Dec 31, 2022	9.00B	1.37B	17.90%
Dec 31, 2021	7.63B	1.47B	23.77%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error